Results 211 to 220 of about 943,135 (348)

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations [PDF]

, 2006
Ángel Lanas, Luis A. Garcı́a Rodrı́guez, M Arroyo, Fernando Gomollón, Faust Feu, Antonio González‐Pérez, E. Zapata, Guillermo Bastida, Luı́s Rodrigo, Santos Santolaria, Maria-Rosa Güell, Carlos Martín de Argila, Enrique Quintero, Fernando Borda, J.M. Piqué   +14 more
openalex   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Estimating the treatment effects of multiple drug combinations on multiple outcomes in hypertension. [PDF]

Cell Rep Med
Liu R, Li L, Zhang P.
europepmc   +1 more source

Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo [PDF]

, 2006
Hans-Guido Wendel, Abba Malina, Zhen Zhao, Lars Zender, Scott C. Kogan, Carlos Cordón-Cardo, Jerry Pelletier, Scott W. Lowe   +7 more
openalex   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

High-throughput approaches to uncover synergistic drug combinations in leukemia. [PDF]

SLAS Discov, 2023
Chory EJ, Wang M, Ceribelli M, Michalowska AM, Golas S, Beck E, Klumpp-Thomas C, Chen L, McKnight C, Itkin Z, Wilson KM, Holland D, Divakaran S, Bradner J, Khan J, Gryder BE, Thomas CJ, Stanton BZ.   +17 more
europepmc   +1 more source

Effect of drug combinations on admission for recurrent myocardial infarction [PDF]

, 2007
Menno E. van der Elst, Marcel L. Bouvy, C. J. De Blaey, A. de Boer   +3 more
openalex   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Melarsoprol-Free Drug Combinations for Second-Stage Gambian Sleeping Sickness: The Way to Go. [PDF]

, 2007
Balasegaram, Brun, F. Chappuis, Priotto, P  pin, P  pin, Van Nieuwenhove   +6 more
core   +2 more sources

DeepTraSynergy: drug combinations using multimodal deep learning with transformers. [PDF]

Bioinformatics, 2023
Rafiei F, Zeraati H, Abbasi K, Ghasemi JB, Parsaeian M, Masoudi-Nejad A.   +5 more
europepmc   +1 more source